Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPMARC pilot study of maraviroc for HIV-associated NAFLD
ISRCTN31461655Phase 4Completed
- Sponsor
- University Hospitals Sussex NHS Foundation Trust
- Start
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of maraviroc in metabolic dysfunction-associated steatotic liver disease (MASLD) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by University Hospitals Sussex NHS Foundation Trust. Primary endpoints: Recruitment feasibility, Monthly recruitment rate and 4 more. Started Mar 2018; status: completed.
02
Drugs
maraviroc
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ISRCTN31461655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31461655.